B. Riley restated their buy rating on shares of Nevro Corp. (NYSE:NVRO) in a research note released on Friday.

A number of other equities research analysts have also recently issued reports on NVRO. Bank of America Corp. initiated coverage on shares of Nevro Corp. in a research report on Monday, August 8th. They issued a buy rating for the company. William Blair reissued an outperform rating on shares of Nevro Corp. in a research report on Monday, July 18th. Wells Fargo & Co. initiated coverage on shares of Nevro Corp. in a research report on Tuesday, July 12th. They issued an outperform rating for the company. Finally, Piper Jaffray Cos. initiated coverage on shares of Nevro Corp. in a research report on Friday, July 22nd. They issued an overweight rating for the company. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $76.75.

Shares of Nevro Corp. (NYSE:NVRO) opened at 98.37 on Friday. Nevro Corp. has a 12 month low of $36.51 and a 12 month high of $100.83. The stock’s 50 day moving average is $94.45 and its 200 day moving average is $74.82. The firm’s market cap is $2.80 billion.

Several hedge funds and other institutional investors have recently bought and sold shares of NVRO. Springbok Capital Management LLC boosted its position in Nevro Corp. by 303.8% in the first quarter. Springbok Capital Management LLC now owns 2,685 shares of the company’s stock worth $151,000 after buying an additional 2,020 shares during the period. IFP Advisors Inc boosted its position in Nevro Corp. by 16.5% in the first quarter. IFP Advisors Inc now owns 3,215 shares of the company’s stock worth $181,000 after buying an additional 455 shares during the period. First Republic Investment Management Inc. bought a new position in Nevro Corp. during the first quarter worth approximately $206,000. Seven Eight Capital LLC bought a new position in Nevro Corp. during the first quarter worth approximately $214,000. Finally, Legal & General Group Plc boosted its position in Nevro Corp. by 28.7% in the first quarter. Legal & General Group Plc now owns 4,094 shares of the company’s stock worth $228,000 after buying an additional 912 shares during the period.

About Nevro Corp.

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.